Urs Duthaler1, Benjamin Berger1, Stefan Erb2, Manuel Battegay2, Emili Letang3,4,5, Stefan Gaugler6, Alex Natamatungiro5, Dorcas Mnzava5, Massimiliano Donzelli1, Stephan Krähenbühl1, Manuel Haschke7,8. 1. Division of Clinical Pharmacology & Toxicology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland. 2. Division of Infectious Diseases and Hospital Epidemiology, University and University Hospital Basel, Basel, Switzerland. 3. Swiss Tropical and Public Health Institute, Basel, Switzerland. 4. ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Clinic, Universitat de Barcelona, Barcelona, Spain. 5. Ifakara Health Institute, Ifakara, Tanzania. 6. CAMAG, Muttenz, Switzerland. 7. Clinical Pharmacology and Toxicology, Department of General Internal Medicine, Inselspital, University Hospital, Bern, Switzerland. 8. Institute of Pharmacology, University of Bern, Bern, Switzerland.
Abstract
Objectives: We evaluated whether dried blood spots (DBS) are suitable to monitor combined ART when samples are collected in rural Tanzania and transported over a long distance to a specialized bioanalytical laboratory. Methods: Plasma and DBS samples were collected in Tanzania from study patients treated with nevirapine, efavirenz or lopinavir. In addition, plasma, whole blood and DBS samples were obtained from a cohort of HIV patients at the site of the bioanalytical laboratory in Switzerland. DBS samples were analysed using a fully automated LC-MS/MS method. Results: Comparison of DBS versus plasma concentrations of samples obtained from the bridging study in Switzerland indicated an acceptable bias only for nevirapine (18.4%), whereas for efavirenz and lopinavir a pronounced difference of -47.4% and -48.1% was found, respectively. Adjusting the DBS concentrations by the haematocrit and the fraction of drug bound to plasma proteins removed this bias [efavirenz +9.4% (-6.9% to +25.7%), lopinavir +2.2% (-20.0% to +24.2%)]. Storage and transportation of samples from Tanzania to Switzerland did not affect the good agreement between plasma and DBS for nevirapine [-2.9% (-34.7% to +29.0%)] and efavirenz [-9.6% (-42.9% to +23.8%)]. For lopinavir, however, adjusted DBS concentrations remained considerably below [-32.8% (-70.4% to +4.8%)] corresponding plasma concentrations due to decay of lopinavir in DBS obtained under field conditions. Conclusions: Our field study shows that the DBS technique is a suitable tool for therapeutic drug monitoring in resource-poor regions; however, sample stability remains an issue for certain analytes and therefore needs special consideration.
Objectives: We evaluated whether dried blood spots (DBS) are suitable to monitor combined ART when samples are collected in rural Tanzania and transported over a long distance to a specialized bioanalytical laboratory. Methods: Plasma and DBS samples were collected in Tanzania from study patients treated with nevirapine, efavirenz or lopinavir. In addition, plasma, whole blood and DBS samples were obtained from a cohort of HIVpatients at the site of the bioanalytical laboratory in Switzerland. DBS samples were analysed using a fully automated LC-MS/MS method. Results: Comparison of DBS versus plasma concentrations of samples obtained from the bridging study in Switzerland indicated an acceptable bias only for nevirapine (18.4%), whereas for efavirenz and lopinavir a pronounced difference of -47.4% and -48.1% was found, respectively. Adjusting the DBS concentrations by the haematocrit and the fraction of drug bound to plasma proteins removed this bias [efavirenz +9.4% (-6.9% to +25.7%), lopinavir +2.2% (-20.0% to +24.2%)]. Storage and transportation of samples from Tanzania to Switzerland did not affect the good agreement between plasma and DBS for nevirapine [-2.9% (-34.7% to +29.0%)] and efavirenz [-9.6% (-42.9% to +23.8%)]. For lopinavir, however, adjusted DBS concentrations remained considerably below [-32.8% (-70.4% to +4.8%)] corresponding plasma concentrations due to decay of lopinavir in DBS obtained under field conditions. Conclusions: Our field study shows that the DBS technique is a suitable tool for therapeutic drug monitoring in resource-poor regions; however, sample stability remains an issue for certain analytes and therefore needs special consideration.
Authors: David Allaway; Janet E Alexander; Laura J Carvell-Miller; Rhiannon M Reynolds; Catherine L Winder; Ralf J M Weber; Gavin R Lloyd; Andrew D Southam; Warwick B Dunn Journal: Front Vet Sci Date: 2022-06-22
Authors: Darrell H S Tan; Adrienne K Chan; Peter Jüni; George Tomlinson; Nick Daneman; Sharon Walmsley; Matthew Muller; Rob Fowler; Srinivas Murthy; Natasha Press; Curtis Cooper; Todd Lee; Tony Mazzulli; Allison McGeer Journal: Trials Date: 2021-03-22 Impact factor: 2.279
Authors: Tanja R Zijp; Zamrotul Izzah; Daan J Touw; Job F M van Boven; Christoffer Åberg; C Tji Gan; Stephan J L Bakker Journal: Drugs Date: 2021-11-01 Impact factor: 9.546